Arrin Kontos
YOU?
Author Swipe
View article: Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy Open
Clinical bleeding events are reported here from 773 patients with B‐cell malignancies receiving pirtobrutinib monotherapy from the phase 1/2 BRUIN study (ClinicalTrials.gov identifier: NCT03740529), either in the presence or absence of ant…
View article: P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS
P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS Open
Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Though covalent Bruton tyrosine kinase inhibitors (BTKi) greatly improved outcomes in patients with B-cell malignancies, they are associated with an increased …